Abstract: The present application relates to compounds of Formula I comprising an antibody binding domain (ABD) comprising a hapten that binds to an antibody in a subject, the antibody comprising a hapten binding site, an antibody labelling domain (ALD) comprising a functional group that forms a covalent bond with an amino acid in the antibody that is proximal to the hapten binding site and the formation of the covalent bond results in elimination of the ABD and either a target binding domain (TBD) or a detection moiety domain (DMD), each domain being optionally connected with independently selected linkers. The present application also includes methods and uses of the compounds, for example, for immune recognition of target cells by recruited labelled antibodies.

Abstract: The present invention provides a method for detecting variant cell-free DNA (cfDNA) in a sample obtained from a subject, where analysis of the sample includes a size-selection step which separates out different fragment sizes of DNA. The sample may be a limited volume sample such as a blood, serum or plasma sample of less than 500 ?l (e.g. a blood or plasma sample of about 50 ?l), or other sample that has a low content of cfDNA. The sample may have been stored and/or dried and not have been processed to remove cells or cellular material prior to storage. The size-selection step may comprise filtering-out, depleting or removing genomic DNA (gDNA) fragments of >200 bp, >300 bp, >500 bp, >700 bp, >1000 bp, >1200 bp, >1500 bp, or >2000 bp prior to analysis, e.g. prior to DNA sequencing. The method may further comprise performing an analysis that summarises or combines data across multiple loci.